ImmunoGen, Inc.
IMGN · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $109 | $70 | $132 | $82 |
| % Growth | 55.7% | -47.2% | 60.8% | – |
| Cost of Goods Sold | $0 | $0 | $115 | $115 |
| Gross Profit | $109 | $70 | $18 | -$32 |
| % Margin | 99.8% | 100% | 13.4% | -39.2% |
| R&D Expenses | $213 | $151 | $115 | $115 |
| G&A Expenses | $0 | $44 | $39 | $38 |
| SG&A Expenses | $116 | $44 | $39 | $38 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$1 | -$1 | $1 | $5 |
| Operating Expenses | $329 | $195 | $153 | $153 |
| Operating Income | -$221 | -$125 | -$135 | -$92 |
| % Margin | -203.1% | -179% | -102.4% | -112% |
| Other Income/Exp. Net | $3 | -$1 | -$22 | -$12 |
| Pre-Tax Income | -$222 | -$139 | -$44 | -$104 |
| Tax Expense | $1 | $0 | $22 | $18 |
| Net Income | -$223 | -$139 | -$67 | -$122 |
| % Margin | -204.9% | -199.4% | -50.4% | -148.4% |
| EPS | -0.879 | -1.081 | -0.38 | -0.82 |
| % Growth | 18.7% | -184.6% | 53.7% | – |
| EPS Diluted | -0.879 | -1.081 | -0.38 | -0.82 |
| Weighted Avg Shares Out | 254 | 206 | 176 | 148 |
| Weighted Avg Shares Out Dil | 254 | 206 | 176 | 148 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $1 | $4 |
| Interest Expense | $4 | $13 | $23 | $17 |
| Depreciation & Amortization | $2 | $2 | $116 | $26 |
| EBITDA | -$216 | -$124 | -$20 | -$66 |
| % Margin | -198.3% | -177.8% | -14.9% | -79.9% |